These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 38002282)

  • 21. Update on Novel Blood-Based Biomarkers for Lupus Nephritis Beyond Diagnostic Approaches.
    Maravillas-Montero JL; Reyes-Huerta RF
    Rev Invest Clin; 2022; 74(5):227-231. PubMed ID: 36327996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Levels of Transforming Growth Factor Beta -1 (TGF-β1) as An Early No Invasive Marker for Diagnosis of Lupus Nephritis in Systemic Lupus Erythematosus Patients.
    Rashad NM; El-Shabrawy RM; Said D; El-Shabrawy SM; Emad G
    Egypt J Immunol; 2019 Jan; 26(1):31-42. PubMed ID: 31332994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review.
    Zhang C; Zeng M; Ge Y; Liu K; Xing C; Mao H
    Front Immunol; 2022; 13():977377. PubMed ID: 36172377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lupus Nephritis: New and Emerging Biologic and Targeted Therapies.
    Kale A; Lech M; Anders HJ; Gaikwad AB
    BioDrugs; 2023 Jul; 37(4):463-475. PubMed ID: 37093522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab in systemic lupus erythematosus and lupus nephritis.
    Beckwith H; Lightstone L
    Nephron Clin Pract; 2014; 128(3-4):250-4. PubMed ID: 25471633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases.
    de la Rubia Navarro M; Ivorra Cortés JR; Grau García E; Román Ivorra JA
    Med Clin (Barc); 2022 Oct; 159(7):344-346. PubMed ID: 35811138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
    Yap DYH; Chan TM
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.
    Zhang H; Chen J; Zhang Y; Zhao N; Xu D
    Ren Fail; 2023 Dec; 45(1):2207671. PubMed ID: 37194710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absolute quantification and characterization of oxylipins in lupus nephritis and systemic lupus erythematosus.
    He J; Ma C; Tang D; Zhong S; Yuan X; Zheng F; Zeng Z; Chen Y; Liu D; Hong X; Dai W; Yin L; Dai Y
    Front Immunol; 2022; 13():964901. PubMed ID: 36275708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-35 as a New Biomarker of Renal Involvement in Lupus Nephritis Patients.
    He D; Liu M; Liu B
    Tohoku J Exp Med; 2018 Apr; 244(4):263-270. PubMed ID: 29576585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic test accuracy of novel biomarkers for lupus nephritis-An overview of systematic reviews.
    Guimarães JAR; Furtado SDC; Lucas ACDS; Mori B; Barcellos JFM
    PLoS One; 2022; 17(10):e0275016. PubMed ID: 36215243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report.
    Huang L; Qian G; Zhang H; Li Q; Chen L; Tang X; Zhao H
    Lupus; 2024 Feb; 33(2):172-175. PubMed ID: 38081170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical application of protein biomarkers in lupus erythematosus and lupus nephritis.
    Qi S; Chen Q; Xu D; Xie N; Dai Y
    Lupus; 2018 Sep; 27(10):1582-1590. PubMed ID: 29720035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus.
    Aljaberi N; Wenderfer SE; Mathur A; Qiu T; Jose S; Merritt A; Rose J; Devarajan P; Huang B; Brunner H
    Lupus Sci Med; 2022 May; 9(1):. PubMed ID: 35568436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk and Factors associated with disease manifestations in systemic lupus erythematosus - lupus nephritis (RIFLE-LN): a ten-year risk prediction strategy derived from a cohort of 1652 patients.
    Chan SCW; Wang YF; Yap DYH; Chan TM; Lau YL; Lee PPW; Lai WM; Ying SKY; Tse NKC; Leung AMH; Mok CC; Lee KL; Li TWL; Tsang HHL; Yeung WWY; Ho CTK; Wong RWS; Yang W; Lau CS; Li PH
    Front Immunol; 2023; 14():1200732. PubMed ID: 37398664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and Emerging Therapy on Lupus Nephritis.
    Bawazier LA
    Acta Med Indones; 2017 Oct; 49(4):369-377. PubMed ID: 29348390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary dedifferentiated podocytes as a non-invasive biomarker of lupus nephritis.
    Perez-Hernandez J; Olivares MD; Forner MJ; Chaves FJ; Cortes R; Redon J
    Nephrol Dial Transplant; 2016 May; 31(5):780-9. PubMed ID: 26932688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The lupus nephritis management renaissance.
    Mejia-Vilet JM; Malvar A; Arazi A; Rovin BH
    Kidney Int; 2022 Feb; 101(2):242-255. PubMed ID: 34619230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kidney outcomes for children with lupus nephritis.
    Oni L; Wright RD; Marks S; Beresford MW; Tullus K
    Pediatr Nephrol; 2021 Jun; 36(6):1377-1385. PubMed ID: 32725543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.